Plazomicin: an investigational therapy for the treatment of urinary tract infections

Bibliography

• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268-81
   PubMed Web of Science ®Google Scholar
• Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1-12
   PubMed Web of Science ®Google Scholar
• Tzouvelekis LS, Markogiannakis A, Psichogiou M, et al. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 2012;25:682-707
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother 2014;15:1351-70
   PubMed Web of Science ®Google Scholar
• Aggen JB, Armstrong ES, Goldblum AA, et al. Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob Agents Chemother 2010;54:4636-42
   PubMed Web of Science ®Google Scholar
• Jana S, Deb J K. Molecular understanding of aminoglycoside action and resistance. Appl Microbiol Biotechnol 2006;70:140-50
   PubMed Web of Science ®Google Scholar
• Wachino J, Arakawa Y. Exogenously acquired 16S rRNA methyltransferases found in aminoglycoside-resistant pathogenic Gram-negative bacteria: An update. Drug Res Updates 2012;15:133-48
   PubMed Web of Science ®Google Scholar
• Galani I, Moraitou E, Orlandou K, et al. Prevalence of 16S rRNA methylase genes in Enterobacterial isolates in two Greek hospitals in a three year period Abstract P1010. 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 10-13 May 2014; Barcelona, Spain
   Google Scholar
• Doi Y, Arakawa Y. 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. Clin Infect Dis 2007;45:88-94
   PubMed Web of Science ®Google Scholar
• Galani I, Souli M, Panagea T, et al. Prevalence of 16S rRNA methylase genes in enterobacteriaceae isolates from a greek University Hospital. Clin Microbiol Infect 2012;18:E52-4
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Warner M, et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother 2011;66:48-53
   PubMed Web of Science ®Google Scholar
• Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002;34:634-40
   PubMed Web of Science ®Google Scholar
• Poole K. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 2005;56:20-51
   PubMed Web of Science ®Google Scholar
• Armstrong ES, Miller GH. Combating evolution with intelligent design: the neoglycoside ACHN-490. Curr Opin Microbiol 2010;13:565-73
   PubMed Web of Science ®Google Scholar
• Franklin K, Clarke AJ. Overexpression and characterization of the chromosomal Aminoglycoside 29-N-acetyltransferase of Providencia stuartii. Antimicrob Agents Chemother 2001;45:2238-44
   PubMed Web of Science ®Google Scholar
• Almaghrabi R, Clancy CJ, Doi Y, et al. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents. Antimicrob Agents Chemother 2014;58:4443-51
   PubMed Web of Science ®Google Scholar
• Galani I, Souli M, Daikos GL, et al. Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece. J Chemother 2012;24:191-4
   PubMed Web of Science ®Google Scholar
• Endimiani A, Hujer KM, Hujer AM, et al. ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. Antimicrob Agents Chemother 2009;53:4504-7
   PubMed Web of Science ®Google Scholar
• Walkty A, Adam H, Baxter M, et al. In vitro activity of plazomicin against 5,015 Gram-negative and Gram-positive clinical isolates obtained from patients in Canadian hospitals as part of the CANWARD study, 2011-2012. Antimicrob Agents Chemother 2014;58:2554-63
   PubMed Web of Science ®Google Scholar
• Landman D, Kelly P, Backer M, et al. Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City. J Antimicrob Chemother 2011;66:332-4
   PubMed Web of Science ®Google Scholar
• Heine HS, Miller L, Halasohoris S, et al. Activity and efficacy of ACHN-490, a broad-spectrum next generation aminoglycoside, against Yersinia pestis and Francisella tularensis Abstract 210. 48th Infectious Diseases Society of America (IDSA) Annual Meeting; 21 – 24 October 2010; Vancouver, BC
   Google Scholar
• Olsen SC, Carlson SA. In vitro bactericidal activity of aminoglycosides, including the next-generation drug plazomicin, against Brucella spp. Int J Antimicrob Agents 2015;45:76-8
   PubMed Web of Science ®Google Scholar
• Tenover FC, Tickler I, Armstrong ES, et al. Activity of ACHN-490 against methicillin-resistant Staphylococcus aureus (MRSA) isolates from patients in US hospitals. Int J Antimicrob Agents 2011;38:352-4
   PubMed Web of Science ®Google Scholar
• Lin G, Ednie LM, Appelbaum PC. Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay. Antimicrob Agents Chemother 2010;54:2258-61
   PubMed Web of Science ®Google Scholar
• Zurenko G, Stapert D, Knechtel M, et al. The bactericidal activity of the neoglycoside ACHN-490 against aminoglycoside-resistant bacteria Abstract F1–841. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 12 – 15 September 2009; San Francisco, CA
   Google Scholar
• Pankuch GA, Lin G, Kubo A, et al. Activity of ACHN-490 tested alone and in combination with other agents against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2011;55:2463-5
   PubMed Web of Science ®Google Scholar
• Pillar CM, Stoneburner A, Serio AW. Plazomicin is potent alone and in combination with other broad-spectrum agents, with no antagonism, against KPC producing Klebsiella pneumoniae Abstract E-1168B. 53th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 10 – 13 September 2013; Denver, CO
   Google Scholar
• Cass RT, Brooks CD, Havrilla NA, et al. Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects. Antimicrob Agents Chemother 2011;55(12):5874-80
   PubMed Web of Science ®Google Scholar
• Van Wart SA, Bhavnani SM, Forrest A, et al. Population Pharmacokinetics of ACHN-490 Injection in Healthy Subjects Abstract 209. 48th Annual Meeting of Infectious Diseases Society of America (IDSA); 21 – 24 October 2010; Vancouver
   Google Scholar
• Van Wart SA, Forrest A, Drusano GL, et al. Pharmacokinetic-pharmacodynamics (PK-PD) predict a high probability of efficacy for plazomicin against serious infections caused by carbapenem-resistant Enterobacteriaceae (CRE) Abstract P-914. 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 27 – 30 April 2013; Berlin
   Google Scholar
• VanWart SA, Forrest A, Bulik CC, et al. Pharmacokinetic/Pharmacodynamic (PK/PD) Assessment Predicts High Efficacy for Plazomicin Against Serious Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae (CR Kp) Abstract A-1054c. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 10 – 13 September 2013; Denver
   Google Scholar
• Zhanel GG, Lawson CD, Zelenitsky S, et al. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev Anti Infect Ther 2012;10(4):459-73
   PubMed Web of Science ®Google Scholar
• Riddle VD, Cebrik D, Kostrub C, et al. The pharmacokinetics (PK) and safety of plazomicin in subjects with renal impairment Abstract P-918. 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 27 – 30 April 2013; Berlin
   Google Scholar
• Cass R, Kostrub CF, Gotfried M, et al. A double-blind, randomized, placebo-controlled study to assess the safety, tolerability, plasma pharmacokinetics and lung penetration of intravenous plazomicin in healthy subjects Abstract P-1637. 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 27 – 30 April 2013; Berlin
   Google Scholar
• Dull WL, Alexander MR, Kasik JE. Bronchial secretion levels of amikacin. Antimicrob Agents Chemother 1979;16(6):767-71
   PubMed Web of Science ®Google Scholar
• Galani I. Plazomicin. Aminoglycoside antibiotic. Drugs Future 2014;39(1):25-35
   Google Scholar
• Riddle V, Mason J, Cebrik D, et al. The Effect of Plazomicin Injection on the QT/QTc Interval in Healthy Volunteers Abst A-017f. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 10 – 13 September 2013; Denver
   Google Scholar
• Riddle V, Cebrik D, Armstrong E, et al. Plazomicin Safety and Efficacy in Patients with Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) Abstract L2-2118a. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 9 – 12 September 2012; San Francisco
   Google Scholar
• Connolly L, Serio A, Riddle V, et al. Baseline Pathogens and Patient Outcomes in a Phase 2 Study Comparing Plazomicin (ACHN-490) to Levofloxacin in Complicated Urinary Tract Infection (cUTI) including Acute Pyelonephritis (AP) presentation O200. 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 25 – 28 April 2015; Copehhagen
   Google Scholar
• Vidal L, Gafter-Gvili A, Borok S, et al. Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2007;60(2):247-57
   PubMed Web of Science ®Google Scholar
• A study of plazomicin compared with colistin in patients with infection due to carbapenem-resistant enterobacteriaceae (CRE). ClinicalTrials.gov Identifier: NCT01970371 Available from: www.clinicaltrials.gov [ [Last accessed August 2015]
   Google Scholar
• A study of plazomicin compared with meropenem for the treatment of complicated urinary tract infection (cUTI) including acute pyelonephritis (AP). ClinicalTrials.gov Identifier: NCT02486627 Available from: www.clinicaltrials.gov [ Last accessed June 2015]
   Google Scholar
• Kostrub C, Dolan D, Altschuler R, et al. Ototoxic potential of ACHN-490 compared to gentamicin and amikacin in the quinea pig Abstract P-1249. 20th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 10 – 13 April 2010; Vienna
   Google Scholar
• Poulikakos P, Falagas ME. Aminoglycoside therapy in infectious diseases. Expert Opin Pharmacother 2013;14(12):1585-97
   PubMed Web of Science ®Google Scholar
• Badal R, Lob S, Mackel M, et al. In vitro activity of ACHN-490 against recent respiratory tract pathogens Abstract E-131. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 17 – 20 September 2011; Chicago, IL
   Google Scholar
• Landman D, Babu E, Shah N, et al. Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City. J Antimicrob Chemother 2010;65:2123-7
   PubMed Web of Science ®Google Scholar